Eicke Latz from 364 Plantation St, Worcester, MA 01605, age 54, Phone: (508)7350759

Toll-Like Receptor Assays
view source
US Patent:

8124349, Feb 28, 2012
Filed:

Jan 6, 2006
Appl. No.:

11/326963
Inventors:

Eicke Latz - Shrewsbury MA, US
Alberto Visintin - Worcester MA, US
Douglas T. Golenbock - Wellesley MA, US
Assignee:

University of Massachusetts - Shrewsbury MA
International Classification:

G01N 33/53
G01N 33/00
C12Q 1/66
C12P 21/04
C07K 1/00
C07K 14/00
US Classification:

435 71, 435 72, 435 75, 435 792, 435 8, 435 697, 530350, 530402
Abstract:

Methods of identifying compounds that modulate the interaction between a TLR and a molecule that interacts with the TLR by direct binding or by inclusion in a complex that associates with the TLR are described. Methods of identifying molecules that interact with a TLR are also described.

Intracellular Dna Receptor
view source
US Patent:

8334101, Dec 18, 2012
Filed:

Sep 25, 2009
Appl. No.:

12/586662
Inventors:

Eicke Latz - Worcester MA, US
Veit Hornung - Pullach, DE
Katherine A. Fitzgerald - Wellesley MA, US
Assignee:

University of Massachusetts - Shrewsbury MA
International Classification:

G01N 33/53
US Classification:

435 71
Abstract:

Provided herein are methods of identifying and using compounds that modulate an AIM2 polypeptide-mediated immune response. Further provided herein are methods of treating disease comprising administering to a patient a compound that decreases expression of an AIM2 polypeptide. Further provided herein are methods of providing gene therapy to a patient comprising administering to the patient a gene therapy agent and a compound that decreases expression of an AIM2 polypeptide. In certain embodiments, a compound that decreases expression of an AIM2 polypeptide comprises an siRNA or an shRNA.

Fluorescent Proteins And Related Methods And Compounds
view source
US Patent:

8617838, Dec 31, 2013
Filed:

Sep 20, 2005
Appl. No.:

11/575363
Inventors:

Eicke Latz - Worcester MA, US
Brian G. Monks - Sudbury MA, US
Douglas T. Golenbock - Wellesley MA, US
Assignee:

University of Massachusetts - Boston MA
International Classification:

C07K 1/00
C07K 4/00
C12Q 1/02
C12N 15/63
C12N 5/00
US Classification:

435 29, 436 8, 436 86, 4353201, 435325, 536 231
Abstract:

The invention includes fusion polypeptides including a first fluorescent protein, e. g. , a FRET donor protein, a second fluorescent protein, e. g. , a FRET acceptor protein, and, linked to at least one of the fluorescent (e. g. , FRET donor or FRET acceptor) proteins, an Fc-region of an immunoglobulin. The polypeptide can be immobilized with respect to a surface via the Fc-region even in the absence of antibodies to either the FRET donor protein or FRET acceptor protein, and can be used as a calibration standard for fluorescence resonance energy transfer includes a polypeptide.

Toll-Like Receptor Assays
view source
US Patent:

20050208470, Sep 22, 2005
Filed:

Dec 16, 2004
Appl. No.:

11/014351
Inventors:

Eicke Latz - Boston MA, US
Alberto Visintin - Worcester MA, US
Douglas Golenbock - Wellesley MA, US
Assignee:

University of Massachusetts - Boston MA
International Classification:

C12Q001/00
G01N033/53
US Classification:

435004000, 435007500
Abstract:

Methods of identifying compounds that modulate the interaction between a TLR and a molecule that interacts with the TLR by direct binding or by inclusion in a complex that associates with the TLR are described. Methods of identifying molecules that interact with a TLR are also described.

Toll-Like Receptor 9 Modulators
view source
US Patent:

20050255451, Nov 17, 2005
Filed:

Dec 16, 2004
Appl. No.:

11/014367
Inventors:

Eicke Latz - Boston MA, US
Alberto Visintin - Worcester MA, US
Douglas Golenbock - Wellesley MA, US
International Classification:

C12Q001/00
US Classification:

435004000
Abstract:

TLR9 is localized to endoplasmic reticulum and upon stimulation with a TLR9 ligand, is transported to a tubular lysosomal compartment as is CpG-DNA. Furthermore, it is shown that TLR9 and CpG-DNA directly bind. It was also found that the MyD88 translocates in response to activation of TLR9-mediated signaling. Methods of identifying compounds that affect translocation and activity of TLR9 and MyD88 are described.

Toll-Like Receptor 9 Modulators
view source
US Patent:

20060127884, Jun 15, 2006
Filed:

Jan 26, 2006
Appl. No.:

11/341319
Inventors:

Eicke Latz - Boston MA, US
Alberto Visintin - Worcester MA, US
Douglas Golenbock - Wellesley MA, US
International Classification:

C12Q 1/00
C12Q 1/68
G01N 33/53
US Classification:

435004000, 435006000, 435007100
Abstract:

TLR9 is localized to endoplasmic reticulum and upon stimulation with a TLR9 ligand, is transported to a tubular lysosomal compartment as is CpG-DNA. Furthermore, it is shown that TLR9 and CpG-DNA directly bind. It was also found that the MyD88 translocates in response to activation of TLR9-mediated signaling. Methods of identifying compounds that affect translocation and activity of TLR9 and MyD88 are described.

Toll-Like Receptor 9 Modulators
view source
US Patent:

20100291577, Nov 18, 2010
Filed:

May 25, 2010
Appl. No.:

12/787009
Inventors:

EICKE LATZ - BOSTON MA, US
ALBERTO VISINTIN - WORCESTER MA, US
DOUGLAS T. GOLENBOCK - WELLESLEY MA, US
Assignee:

UNIVERSITY OF MASSACHUSETTS - BOSTON MA
International Classification:

C12Q 1/68
G01N 33/566
US Classification:

435 6, 435 721, 436 86
Abstract:

TLR9 is localized to endoplasmic reticulum and upon stimulation with a TLR9 ligand, is transported to a tubular lysosomal compartment as is CpG-DNA. Furthermore, it is shown that TLR9 and CpG-DNA directly bind. It was also found that the MyD88 translocates in response to activation of TLR9-mediated signaling. Methods of identifying compounds that affect translocation and activity of TLR9 and MyD88 are described.

Eicke Latz